NFE2L2 and hepatocellular carcinoma: Rather, when liver tumorigenesis is in progress, GSH supplementation reduces intracellular ROS levels and desensitizes the Nrf2/GCLC antioxidant signaling pathway, thus increasing the incidence of HCC [9].